A classroom reflecting life's diversity will benefit children of all strata while enriching teaching experience. Now that the Supreme Court has validated the Right to Education (RTE), its success will depend on teachers. When I said this to a friend who teaches in a primary school, she said, “you are being unfair.” I was startled to hear this response because what I had said was common sense. When I pointed this...
More »SEARCH RESULT
UN calls attention to rising number of dementia cases, urges early detection
-The United Nations The number of people with dementia is projected to double to 65.7 million by 2030, the United Nations World Health Organization (WHO) said today, noting that lack of diagnosis remains a major problem even in high-income countries, where only a fifth to half of cases are routinely recognized. Treating and caring for the estimated 35.6 million with dementia at present costs the world more than $604 billion per year,...
More »Madrasas waiting for amendment to RTE Act-JS Ifthekhar
Madrasa managements across the country are keenly watching the budget session of Parliament. No, they are not looking forward to the kind of budget that will be presented by the Finance Minister. Their anxiety is to see the promised relief coming in the Right to Education (RTE) Act for minority institutions. The government has promised to bring amendments to certain sections of the Act seen as having a ‘negative impact'...
More »The ABCs of RTE
-The Hindu As it stands on the threshold of the Twelfth Plan, India has a historic opportunity to elevate education and healthcare as the strongest pillars of its future development. Yearning for life-building education is unprecedented today. Yet, as Amartya Sen pointed out last year, the system remains deeply unjust. Access to excellence is open to those who can afford it, while the less-affluent majority has been left behind without even...
More »Natco Pharma bags licence to sell Bayer's cancer drug Nexavar
-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision. The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...
More »